[CDNA] CareDx, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization: 94.65 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.85 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CDNA

Refresh chart

Strongest Trends Summary For CDNA

CDNA is in the medium-term down -43% below S&P in 1 year. In the long-term up 750% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: CareDx, Inc. develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient?s lifetime. It provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. The company also offers AlloMap Molecular Expression Testing, an in vitro diagnostic multivariate index assay test service performed in a single laboratory assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells. It markets and sells its products through distribution partners in the United States, Canada, and Europe. CareDx, Inc. was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in April 2014. The company was incorporated in 1998 and is based in Brisbane, Californ

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding18.93 M EPS-1.5 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 6.49% Sales Growth - Q/Q-9.26% P/E-0.73
P/E To EPS Growth P/S3.31 P/BV2.4 Price/Cash Per Share
Price/Free Cash Flow-23.18 ROA-0.3% ROE-0.47% ROI-0.34%
Current Ratio6.74 Quick Ratio6.62 Long Term Debt/Equity0.41 Debt Ratio0.16
Gross Margin68.21% Operating Margin0.3% Net Profit Margin-0.65% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.93 M Cash From Investing Activities-360 K Cash From Operating Activities-1.01 M Gross Profit4.5 M
Net Profit-2.27 M Operating Profit-1.39 M Total Assets63.28 M Total Current Assets42.3 M
Total Current Liabilities6.28 M Total Debt15.66 M Total Liabilities23.81 M Total Revenue7.22 M
Technical Data
High 52 week40.08 Low 52 week19.89 Last close28.41 Last change1%
RSI85.82 Average true range1.43 Beta0.97 Volume12.77 K
Simple moving average 20 days14.92% Simple moving average 50 days18.49% Simple moving average 200 days-3.35%
Performance Data
Performance Week8.98% Performance Month20.03% Performance Quart-8.24% Performance Half0.11%
Performance Year27.86% Performance Year-to-date13.01% Volatility daily2.8% Volatility weekly6.26%
Volatility monthly12.84% Volatility yearly44.46% Relative Volume87.32% Average Volume869.62 K
New High New Low


2020-05-28 07:00:10 | CareDx to Present at the Jefferies Virtual Healthcare Conference

2020-05-27 07:00:10 | CareDx Presents the Latest AlloSure Data in Virtual Meetings

2020-05-15 07:00:10 | CareDx's AlloSeq Tx 17 Awarded CE Mark Approval

2020-05-14 08:15:00 | CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System

2020-05-07 07:00:10 | CareDx Brings the Transplant Patient Community Together

2020-05-05 07:00:10 | CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap

2020-05-02 08:35:56 | Here's Why We're Not At All Concerned With CareDx's NASDAQ:CDNA Cash Burn Situation

2020-05-01 13:00:29 | CareDx Inc CDNA Q1 2020 Earnings Call Transcript

2020-05-01 03:34:42 | Edited Transcript of CDNA earnings conference call or presentation 30-Apr-20 8:30pm GMT

2020-04-30 16:05:10 | CareDx Reports First Quarter 2020 Results

2020-04-27 07:00:10 | CareDx Engages European Lab Community in Virtual Meetings

2020-04-23 12:32:04 | Earnings Preview: CareDx CDNA Q1 Earnings Expected to Decline

2020-04-23 07:00:10 | CareDx and Johns Hopkins Partner on AlloSure Lung Surveillance

2020-04-22 07:00:10 | CareDx Presents New Heart and Lung Transplant Data in Virtual Meetings

2020-04-21 07:00:10 | CareDx to Report First Quarter 2020 Financial Results

2020-04-14 07:00:10 | CareDx Introduces AlloCell: Cell Therapy Surveillance

2020-04-09 07:00:10 | CareDx Mobilizes 10,000 Phlebotomists for Home Blood Draws of Transplant Patients with RemoTraC

2020-04-08 16:01:10 | CareDx Reports Preliminary First Quarter 2020 Revenue and Provides Business Update in Response to COVID-19 Pandemic

2020-04-06 07:00:10 | CareDx Supports Launch of International COVID-19 Transplant Registry C19TxR

2020-04-02 06:44:16 | Is There An Opportunity With CareDx, Inc's NASDAQ:CDNA 54% Undervaluation?

2020-03-23 17:58:30 | Edited Transcript of CDNA earnings conference call or presentation 27-Feb-20 9:30pm GMT

2020-03-20 07:00:10 | REPEAT - New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy

2020-03-20 01:05:59 | New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy

2020-03-17 10:10:02 | Are Options Traders Betting on a Big Move in CareDx CDNA Stock?

2020-03-17 08:48:35 | The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

2020-03-17 07:00:10 | CareDx Launches RemoTraC: Home-Based Monitoring of Transplant Patients

2020-03-12 07:00:10 | CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community

2020-03-05 07:00:10 | CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-optimization Study at CEOT

2020-02-28 07:00:10 | CareDx to Participate in Upcoming Investor Conferences

2020-02-27 16:05:10 | CareDx Reports Fourth Quarter and Full Year 2019 Results

2020-02-27 06:11:41 | Does CareDx, Inc's NASDAQ:CDNA CEO Salary Compare Well With Others?

2020-02-26 07:00:10 | New AJT Publication: AlloSure is the Only cfDNA Test Proven to Differentiate Ambiguous Rejections

2020-02-20 12:31:05 | CareDx CDNA Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2020-02-19 11:18:04 | The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx

2020-02-18 08:47:01 | Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks

2020-02-13 07:00:10 | CareDx to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

2020-02-11 07:00:10 | CareDx’s Patent Rights Upheld By Delaware Court

2020-02-07 12:00:05 | CareDx CDNA Upgraded to Strong Buy: Here's Why

2020-02-06 09:16:02 | US Service Sector Accelerates in January: 5 Stocks to Buy

2020-02-04 08:15:38 | The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

2020-02-04 07:00:10 | CareDx Launches AiTraC Conference

2020-02-03 11:54:44 | 5 Defensive Stocks to Counter Coronavirus Scare

2020-02-03 06:55:11 | Super Bowl Results Show Stock Gains in February: 5 Picks

2020-01-22 16:44:09 | Teladoc TDOC Hits 52-Week High: Will Momentum Sustain?

2020-01-22 06:15:16 | When Will CareDx, Inc NASDAQ:CDNA Breakeven?

2020-01-13 07:00:10 | CareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results

2020-01-10 07:00:10 | CareDx’s AlloSeq cfDNA Awarded CE Mark Approval

2020-01-09 07:00:10 | CareDx Leadership at ASTS Meeting

2020-01-08 07:00:10 | CareDx's False Advertising Complaint Upheld By Court

2019-12-24 07:00:10 | CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635c4